Flash Finance

Medplus Health Services LimitedMEDPLUSCorporate

Pharmacy Retail Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹611.95
MCap ₹7,349 Cr · P/E 117.1
Medplus Health Services Limited — Stock analysis & AI research Medplus Health Services Limited — Seasonality — best & worst months Medplus Health Services Limited — Technical indicators & charts Medplus Health Services Limited — Technical setup — score, trend, support & resistance Medplus Health Services Limited — Falling Wedge pattern forming Medplus Health Services Limited — Live exchange announcements
📋 High Profit Growth Stocks 📈 RSI Oversold Stocks📈 New 52-Week Low Stocks📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹248 Cr
Sales · Mar 2026
+22.8% YoY
₹27 Cr
Operating Profit · Mar 2026
+12.5% YoY
10.9%
OPM % · Mar 2026
-8.4% YoY
₹17 Cr
Net Profit · Mar 2026
+21.4% YoY
₹1.39
EPS · Mar 2026
+18.8% YoY

📝 Medplus Health Services Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Medplus Health Services Limited reported revenue of ₹248 crore for the quarter ended March 2026 (Q4 FY26), up 22.8% from ₹202 crore in the same quarter last year, and up 11.2% sequentially over the December 2025 quarter.

Net profit rose 21.4% year-on-year to ₹17 crore, from ₹14 crore. Earnings per share (EPS) came in at ₹1.39.

Operating profit stood at ₹27 crore — an operating margin (OPM) of 10.9%, compared with 11.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Medplus Health Services Limited posted revenue of ₹861 crore, a growth of 20.6% over FY25, with a net profit of ₹63 crore (up 55.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹861 crore with a net profit of ₹63 crore.

Valuation snapshot

At the current price of ₹611.95, MEDPLUS has a market capitalisation of ₹7,349 crore and a trailing P/E of about 117.1.

Within the Pharmacy Retail industry, it is the largest of the 2 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 40.19%, foreign institutional investors (FIIs) 12.58%, domestic institutional investors (DIIs) 31.89%, public shareholders 15.29% of Medplus Health Services Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹7,349 Cr
Current Price ?
₹612.0
P/E ?
117.13above ind
Industry P/E ?
43.60
P/B ?
5.58
P/S ?
8.54
P/FCF ?
131.23
Enterprise Value ?
₹7,441 Cr
EV/EBITDA ?
69.73
PEG ?
0.93
Earnings Yield ?
1.1%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹861 Cr
OPM ?
12.4%
Profit after tax (TTM) ?
₹63 Cr
EPS (TTM) ?
₹5.22
ROCE ?
7.0%
ROE ?
4.8%
ROA ?
4.3%
Growth
Sales — latest qtr ?
₹248 Cr
PAT — latest qtr ?
₹17 Cr
YoY qtr sales growth ?
22.8%
YoY qtr profit growth ?
21.4%
Sales growth (3y) ?
59%
Sales growth (5y) ?
66%
Profit growth (3y) ?
126%
Profit growth (5y) ?
56%
Financial Health
Debt ?
₹92 Cr
Debt to Equity ?
0.07
Interest Coverage ?
10.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
40.19%
Change in promoter holding ?
-0.13%
Pledged percentage ?
N/A
Market
Return 3 months ?
-23.6%
Return 6 months ?
-30.3%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 5787721,409148148178156177202184206223248 +22.8% +11.2%
Operating Profit 4112611131817192424272927 +12.5% -6.0%
Other Income 43242222233332 -33.3% -25.8%
Interest 22222222222221 -50.0% -58.2%
Depreciation 45666667777775 -28.6% -30.5%
Profit Before Tax 27-316461210121818212223 +27.8% +5.4%
Net Profit 16-303109891414161717 +21.4% +2.6%
EPS 0.150.15-0.29-0.010.270.830.770.650.781.171.131.311.381.39 +18.8% +0.7%
OPM % 6.5% 13.1% 3.2% 0.4% 7.3% 8.7% 10.3% 10.8% 10.6% 11.9% 13.0% 13.2% 12.9% 10.9% -8.4% -15.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹713 Cr ₹861 Cr ₹861 Cr +20.6%
Operating Profit ₹78 Cr ₹107 Cr ₹107 Cr +36.8%
OPM % 10.93% 12.40% 12.40% +13.4%
NPM % 5.66% 7.29% 7.29% +28.8%
Other Income ₹9 Cr ₹10 Cr ₹10 Cr +10.8%
Depreciation ₹27 Cr ₹26 Cr ₹26 Cr -5.4%
Interest ₹9 Cr ₹8 Cr ₹8 Cr -7.3%
EBIT ₹51 Cr ₹81 Cr ₹81 Cr +59.8%
PBT ₹51 Cr ₹83 Cr ₹83 Cr +62.1%
Tax ₹7 Cr ₹14 Cr ₹14 Cr +108.1%
Net Profit ₹40 Cr ₹63 Cr ₹63 Cr +55.4%
EPS ₹3.37 ₹5.21 ₹5.21 +54.6%
Material Cost ₹391 Cr ₹460 Cr ₹460 Cr +17.6%
Employee Cost ₹35 Cr ₹40 Cr ₹40 Cr +12.4%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 24242424 +0.0%
Reserves 1,1171,1641,2161,292 +6.2%
Borrowings 86899592 -3.2%
Other Liabilities 45336557 -12.3%
Total Liabilities 1,2721,3101,3991,465 +4.7%
Fixed Assets 179192184167 -9.2%
CWIP 18012 +100.0%
Investments 917923928931 +0.3%
Other Assets 157196286366 +28.0%
Total Assets 1,2721,3101,3991,465 +4.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1184762 +31.9%
Cash from Investing Activity 32-24-39-22 +43.6%
Cash from Financing Activity -8-6-10-5 +50.0%
Net Cash Flow 35-22-235 +1850.0%
Free Cash Flow -50-33856 +47.4%
CFO/OP 211%33%71%78% +9.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 64546256 -9.7%
Inventory Days 16151215 +25.0%
Days Payable 30193019 -36.7%
Cash Conversion Cycle 50504452 +18.2%
Working Capital Days 21627665 -14.5%
ROCE % 1%1%5%7% +40.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 40.32%40.29%40.29%40.22%40.19%40.19% +0.0%
FIIs 16.43%16.53%16.83%15.53%14.38%12.58% -12.5%
DIIs 26.03%26.51%26.58%27.82%29.95%31.89% +6.5%
Public 17.18%16.60%16.27%16.41%15.44%15.29% -1.0%
Others 0.05%0.05%0.04%0.04%—— —
No. of Shareholders 81,74278,33779,15777,27876,00577,714 +2.2%

⚖️ Peer comparison

Industry: Pharmacy Retail · 2 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 MEDPLUS Medplus Health ₹660.00 7,926 36.0 6,892 220 8.8% 3.2% 12.3% 46.5% 23.4% 25.5%
2 ENTERO Entero Healthcare ₹1,731.80 7,537 58.8 7,128 168 4.4% 2.4% 29.4% 36.3% 38.2% 72.2%
❓ Frequently asked questions
What was Medplus Health Services Limited's revenue in Q4 FY26?
Medplus Health Services Limited reported revenue of ₹248 crore for the quarter ended March 2026 (Q4 FY26), up 22.8% from ₹202 crore in the same quarter last year, and up 11.2% sequentially over the December 2025 quarter.
What was Medplus Health Services Limited's net profit in Q4 FY26?
Net profit rose 21.4% year-on-year to ₹17 crore, from ₹14 crore. Earnings per share (EPS) came in at ₹1.39.
What is MEDPLUS's market capitalisation and P/E ratio?
At the current price of ₹611.95, MEDPLUS has a market capitalisation of ₹7,349 crore and a trailing P/E of about 117.1.
Who owns Medplus Health Services Limited? (shareholding pattern)
As of Sep 2026, promoters held 40.19%, foreign institutional investors (FIIs) 12.58%, domestic institutional investors (DIIs) 31.89%, public shareholders 15.29% of Medplus Health Services Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI